Eva Johansson1, Gunnar Steineck2, Lars Holmberg3, Jan-Erik Johansson4, Tommy Nyberg5, Anna Bill-Axelson6. 1. Department of Surgical Sciences, University Hospital of Uppsala, Uppsala, Sweden. Electronic address: evajson@icloud.com. 2. Division of Clinical Cancer Epidemiology, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. 3. Department of Surgical Sciences, University Hospital of Uppsala, Uppsala, Sweden; Division of Cancer Studies, Medical School, King's College London, London, UK. 4. Department of Urology, Örebro University Hospital, Örebro University, Örebro, Sweden. 5. Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. 6. Department of Surgical Sciences, University Hospital of Uppsala, Uppsala, Sweden.
Abstract
BACKGROUND:Men with prostate cancer experienceadjuvant androgen deprivation therapy (ADT) differently. OBJECTIVE: To evaluate the effect of ADT on quality of life (QoL), patients' experience of clinical check-ups, and differences in cancer information as explanatory factors. DESIGN, SETTING, AND PARTICIPANTS: A study-specific questionnaire was sent to all men randomized in the SPCG-4 trial to radical prostatectomy (RP) or watchful waiting (WW) still alive (400/695) and a control group of 281 men. INTERVENTION: ADT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Self-assessed QoL, worry at clinical check-ups, and amount of information received. Estimated relative risks with associated 95% confidence intervals (CI) for risk comparisons between groups using a log-binomial regression. RESULTS AND LIMITATIONS: The SPCG-4 men had median follow-up of 12.2 yr and median age of 77.0 yr; 26% in the RP group and 40% in the WW group received ADT treatment. High QoL for men without ADT was 36% for the RP group, 44% for the WW group, and 45% for the control group. High QoL for men with ADT was 30% for the RP group and 20% for the WW group. Among men with ADT, those in the WW group received significantly less information about the disease than men in the RP group. Receiving no or little information about prostate cancer was reported by 17% of patients in the RP group and 39% in the WW group among men receiving ADT (relative risk 0.44, 95% CI 0.22-0.89). At clinical check-ups, men treated with ADT had significantly higher levels of worry, regardless of study group, than men without ADT. Limitations include the lack of longitudinal data and a low number of men receiving ADT in the RP group. CONCLUSIONS: Men on WW without ADT reported high QoL comparable to that for men without prostate cancer. ADT treatment in the WW group was associated with the lowest scores for all psychological parameters, and these men reported that they were least informed about prostate cancer and its consequences. PATIENT SUMMARY: Good communication and information from caregivers are associated with less negative psychological effects at prostate cancer progression.
RCT Entities:
BACKGROUND:Men with prostate cancer experience adjuvant androgen deprivation therapy (ADT) differently. OBJECTIVE: To evaluate the effect of ADT on quality of life (QoL), patients' experience of clinical check-ups, and differences in cancer information as explanatory factors. DESIGN, SETTING, AND PARTICIPANTS: A study-specific questionnaire was sent to all men randomized in the SPCG-4 trial to radical prostatectomy (RP) or watchful waiting (WW) still alive (400/695) and a control group of 281 men. INTERVENTION: ADT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Self-assessed QoL, worry at clinical check-ups, and amount of information received. Estimated relative risks with associated 95% confidence intervals (CI) for risk comparisons between groups using a log-binomial regression. RESULTS AND LIMITATIONS: The SPCG-4 men had median follow-up of 12.2 yr and median age of 77.0 yr; 26% in the RP group and 40% in the WW group received ADT treatment. High QoL for men without ADT was 36% for the RP group, 44% for the WW group, and 45% for the control group. High QoL for men with ADT was 30% for the RP group and 20% for the WW group. Among men with ADT, those in the WW group received significantly less information about the disease than men in the RP group. Receiving no or little information about prostate cancer was reported by 17% of patients in the RP group and 39% in the WW group among men receiving ADT (relative risk 0.44, 95% CI 0.22-0.89). At clinical check-ups, men treated with ADT had significantly higher levels of worry, regardless of study group, than men without ADT. Limitations include the lack of longitudinal data and a low number of men receiving ADT in the RP group. CONCLUSIONS:Men on WW without ADT reported high QoL comparable to that for men without prostate cancer. ADT treatment in the WW group was associated with the lowest scores for all psychological parameters, and these men reported that they were least informed about prostate cancer and its consequences. PATIENT SUMMARY: Good communication and information from caregivers are associated with less negative psychological effects at prostate cancer progression.